Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1547 studies found for:    cancer | bevacizumab
Show Display Options
RSS Create an RSS feed from your search for:
cancer | bevacizumab
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab;   Drug: no bevacizumab
2 Completed
Has Results
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: ABI-007;   Drug: Bevacizumab
3 Recruiting Fluorescence Guided Surgery in Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bevacizumab-800CW
4 Completed Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Bevacizumab (Avastin)
5 Recruiting Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: TAS-102 and Bevacizumab
6 Completed
Has Results
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer;   Locally Advanced Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Bevacizumab
7 Completed VEGF Early Imaging for Breast Cancer
Condition: Breast Cancer
Intervention: Other: 89Zr-bevacizumab PET
8 Completed
Has Results
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: Docetaxel
9 Recruiting Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Bevacizumab
10 Active, not recruiting Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Other: no maintenance
11 Completed Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Bevacizumab, docetaxel, cisplatin
12 Completed Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bevacizumab, Abraxane
13 Enrolling by invitation Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Bevacizumab
14 Completed First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer
Condition: Colorectal Cancer Stage II
Intervention: Drug: Bevacizumab and FOLFIRI
15 Completed
Has Results
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Condition: Cancer
Interventions: Drug: Pemetrexed;   Drug: Bevacizumab
16 Active, not recruiting Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: fulvestrant
17 Recruiting Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Maintenance:BEVACIZUMAB;   Drug: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE
18 Terminated
Has Results
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
Condition: Colon Cancer
Intervention: Drug: FOLFOX and bevacizumab
19 Completed VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer
Condition: Breast Cancer
Intervention: Drug: bevacizumab-IRDye800CW
20 Active, not recruiting Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: low-dose-bevacizumab/pemetrexed;   Drug: Treatment of physician's choice

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.